AbTAC Degradation Technology Development

Name: AbTAC Degradation Technology Development
Brand: BOC Sciences

AbTAC (antibody-based proteolysis-targeting chimera) is an emerging targeted protein degradation modality developed to eliminate extracellular and cell-surface proteins that are difficult to address with conventional intracellular PROTAC strategies. Unlike small-molecule degraders that mainly depend on intracellular E3 ligases and proteasomal processing, AbTACs are designed to act at the cell surface and expand targeted degradation to membrane-associated and extracellular proteins with high biological relevance.

Structurally, AbTACs are typically engineered as bispecific or bifunctional antibody-based molecules that simultaneously bind a target membrane or extracellular protein and a cell-surface receptor involved in degradation, thereby inducing target internalization and subsequent lysosomal degradation. Building on this modality, BOC Sciences provides customized AbTAC degradation technology development services covering antibody engineering, target biology evaluation, binder selection, bispecific molecule design, linker optimization, degradation mechanism validation, and functional assay development, helping pharmaceutical, biotechnology, and academic clients generate clearer feasibility data and more actionable candidate-selection insights.

Services

BOC Sciences' Comprehensive AbTAC Development Services

AbTAC Target Feasibility and Biology Assessment Successful AbTAC development begins with a clear understanding of whether the target protein is biologically suitable for antibody-mediated degradation. We assess target localization, extracellular domain accessibility, internalization behavior, disease relevance, expression pattern, available binders, and degradation route compatibility to help clients define a realistic technical strategy before molecule construction. Cell-surface and extracellular target evaluation Target expression, turnover, and internalization analysis Target protein services for target preparation and characterization Feasibility assessment for AbTAC, LYTAC, or other eTPD approaches
Antibody Binder Screening and Engineering Antibody quality strongly influences AbTAC specificity, target engagement, internalization efficiency, and degradation outcome. We support binder selection, affinity evaluation, epitope analysis, format comparison, and antibody engineering to identify antibodies or antibody fragments suitable for AbTAC construction and downstream functional validation. Target-binding antibody or fragment screening Affinity, specificity, and epitope characterization Antibody format comparison, including IgG, Fab, scFv, and nanobody formats Binder prioritization based on degradation-oriented design requirements
AbTAC Molecular Design and Format Optimization We design AbTAC molecules by integrating target-binding modules, degradation-recruiting modules, linker architecture, valency, spatial orientation, and developability considerations. Depending on the project goal, we can support bispecific antibody-like formats, antibody conjugate formats, recombinant fusion formats, or exploratory antibody-based degrader architectures. Bispecific AbTAC architecture design Degradation-recruiting arm selection and pairing strategy PROTAC-antibody conjugates design for antibody-based degrader construction Format comparison for activity, manufacturability, and assay compatibility
Linker and Spatial Geometry Optimization Linker length, flexibility, attachment position, and molecular geometry can determine whether an AbTAC forms a productive target-degrader-receptor complex. We provide systematic linker design and optimization to improve target recruitment, receptor engagement, internalization, and degradation efficiency while reducing steric conflict between antibody domains. Flexible, rigid, cleavable, and non-cleavable linker design Antibody-domain orientation and conjugation site evaluation Linker design and optimization services Iterative optimization based on binding and degradation data
Computational Modeling and Complex Prediction To reduce experimental uncertainty, we use computational modeling to support epitope selection, antibody orientation analysis, receptor-target proximity evaluation, and AbTAC complex design. These insights help clients prioritize constructs with better spatial compatibility before entering synthesis, expression, or functional screening. Antibody-target structural modeling Protein structure modeling In silico protein-protein interactions prediction Construct prioritization based on predicted complex geometry
AbTAC Degradation and Functional Validation We establish degradation assays to evaluate whether designed AbTACs can reduce target protein levels in relevant cell models. Our studies can include dose–response analysis, time-course evaluation, target selectivity, receptor dependency, internalization tracking, lysosomal pathway confirmation, and downstream functional readouts. Cell-based target degradation assays Degradation ability assay Western blot, flow cytometry, ELISA, imaging, or reporter-based readouts Mechanism validation using pathway inhibitors and receptor-dependency studies

Have You Encountered These Challenges in AbTAC Development?

Uncertainty about whether the target protein is suitable for antibody-mediated degradation
Difficulty identifying antibodies with the right epitope, affinity, and internalization behavior
Limited knowledge of which degradation-recruiting pathway or receptor should be used
Poor degradation despite strong target binding
Complex format, linker, valency, and orientation optimization
Lack of reliable assays to distinguish surface masking from true target degradation

Tell Us Your Challenge

Contact us to discuss how we can help you design, validate, and optimize your AbTAC strategy.

Submit Inquiry

Challenge Solving

Our Solutions for Key AbTAC Development Challenges

AbTAC development is not simply a matter of connecting two antibodies. Productive degradation requires target engagement, receptor recruitment, internalization, trafficking, and lysosomal processing to work together. BOC Sciences provides integrated technical solutions to help clients convert early AbTAC concepts into experimentally validated degrader candidates.

Solution for Target Selection and Degradability Assessment We evaluate whether the target is exposed on the cell surface or secreted, whether it has an accessible extracellular domain, whether antibody binding may trigger internalization, and whether degradation would generate meaningful biological insight. For targets with unclear suitability, we compare AbTAC with related extracellular degradation strategies such as lysosomal-based degradation technology development and LYTAC degradation technology development to help clients select the most appropriate research direction.
Solution for Antibody and Epitope Selection When several antibodies bind the same target, their degradation performance may differ significantly due to epitope location, binding kinetics, receptor co-localization, and internalization behavior. We support binder comparison using affinity testing, epitope grouping, cell-surface binding assays, internalization studies, and degradation readouts to identify antibodies that are functionally suitable for AbTAC construction.
Solution for AbTAC Format and Linker Optimization We design multiple AbTAC architectures to test how antibody format, valency, linker length, domain orientation, and attachment position influence degradation. Rather than relying on a single construct, we build focused design matrices that allow clients to compare degradation potency, target selectivity, expression quality, and experimental robustness across different AbTAC formats.
Solution for Mechanism and Degradation Validation AbTAC studies require assays that can distinguish true protein degradation from simple receptor blockade, surface masking, or antibody-induced redistribution. We combine flow cytometry, immunoblotting, imaging, lysosomal pathway analysis, time-course studies, and receptor-dependency experiments to confirm whether target reduction is degradation-driven and whether the mechanism aligns with the intended AbTAC design.

Explore antibody-based degradation for membrane and extracellular targets with BOC Sciences.

From feasibility assessment and antibody design to AbTAC construction and degradation validation, BOC Sciences helps clients build practical, data-driven AbTAC development strategies for early discovery and mechanism-focused research.

Talk to Our Experts

Client Solutions

AbTAC Solutions for Different R&D Organizations

Pharmaceutical Research Teams

For pharmaceutical researchers exploring new modalities beyond small-molecule inhibition, we provide AbTAC feasibility evaluation, target prioritization, construct design, and degradation validation to help assess whether a membrane or extracellular protein can be addressed through antibody-mediated degradation.

Biotechnology Companies

Biotech teams often need rapid proof-of-concept data to support platform building, target selection, or pipeline expansion. We offer flexible AbTAC service modules covering binder screening, format optimization, and cell-based degradation assays to accelerate early technical validation.

Academic and Translational Research Groups

For research groups studying receptor biology, immune signaling, tumor microenvironment proteins, or extracellular disease mediators, we provide customized AbTAC design and assay support to generate mechanistic data and evaluate target degradation hypotheses.

CROs and Technology Platforms

CROs and technical service providers can use our AbTAC capabilities as modular support when projects require antibody-based degradation design, complex assay development, or specialized extracellular targeted protein degradation expertise.

Get a Quote

Workflow

End-to-End AbTAC Development Workflow

01

Project Inquiry and Requirement Collection

We collect target information, available antibodies or ligands, desired degradation outcome, disease research context, assay models, timeline, and expected deliverables.

02

Target Biology and Degradability Assessment

We evaluate target localization, extracellular domain accessibility, internalization behavior, receptor compatibility, and the technical suitability of an AbTAC strategy.

03

Antibody Binder Review and Selection

Existing antibodies are reviewed or new binders are screened based on affinity, specificity, epitope position, cell-surface binding, and degradation-oriented design value.

04

AbTAC Format and Linker Design

We design AbTAC constructs by optimizing antibody format, valency, linker length, domain orientation, and degradation-recruiting module selection.

05

Construct Preparation and Quality Evaluation

Selected AbTAC constructs are prepared and evaluated for expression, purity, binding retention, structural integrity, and assay readiness.

06

Binding, Internalization, and Degradation Testing

We assess target engagement, cell-surface binding, internalization behavior, degradation efficiency, dose response, and time-dependent target reduction.

07

Mechanism Confirmation and Optimization

Mechanistic studies are performed to confirm lysosomal pathway involvement, receptor dependency, selectivity, and functional consequences of target degradation.

08

Data Reporting and Next-Round Design Recommendation

We deliver experimental data, construct comparison results, interpretation, and practical recommendations for the next round of AbTAC optimization.

Advantages

Advantages of AbTAC Degradation Technology

Expands TPD to Cell-Surface Targets

AbTACs provide a research strategy for degrading membrane-associated proteins that are not accessible to traditional intracellular PROTAC molecules.

Leverages Antibody Specificity

Antibody recognition enables selective target engagement, making AbTACs attractive for proteins with disease-relevant extracellular domains or cell-type-specific expression.

Supports Difficult Target Classes

AbTAC technology may be useful for receptors, immune checkpoints, cell adhesion proteins, and other targets where inhibition alone may not fully address protein function.

Enables Mechanism-Focused Discovery

By removing the target protein from the cell surface, AbTACs help researchers investigate biology beyond receptor blockade, including trafficking, turnover, and signaling dependence.

Applications

Applications Supported by Our AbTAC Development Platform

Immune Checkpoint and Immuno-Oncology Targets

Degradation-oriented research for PD-L1 and other cell-surface immune regulators
Evaluation of antibody-mediated target removal versus receptor blockade
Functional studies in immune signaling and tumor cell interaction models
Support for exploratory immuno-oncology target validation

Receptor Tyrosine Kinases and Disease-Associated Receptors

AbTAC design for membrane receptors with accessible extracellular domains
Degradation studies for receptor abundance, signaling, and turnover analysis
Exploration of targets such as EGFR-related membrane protein systems
Related target strategy support through PROTAC Targeting EGFR

Secreted and Extracellular Disease Mediators

Feasibility exploration for extracellular protein depletion
Binder and receptor-pairing strategy development
Assay setup for protein reduction and pathway modulation
Comparison with other extracellular targeted degradation modalities

Platform and Modality Comparison Studies

AbTAC versus LYTAC strategy comparison
Evaluation of antibody-based, lysosomal, and alternative degrader formats
Support for alternative PROTAC technology development
Data-driven recommendation for target-appropriate degradation strategies

Case Study

Client Success Stories: AbTAC Degradation Technology Development

Project Background

A biopharmaceutical company aimed to develop a next-generation protein degrader targeting PD-L1. Unlike traditional monoclonal antibodies that only block the PD-1/PD-L1 interaction, the client wanted to achieve complete removal of the PD-L1 protein from the cell surface to overcome potential compensatory upregulation. The primary challenge was selecting a suitable transmembrane E3 ligase and engineering a bispecific antibody structure that could efficiently induce endocytosis without premature degradation of the AbTAC itself.

Our Support

We utilized our AbTAC technology platform to recruit the E3 ligase RNF43, which is highly expressed in specific tumor environments. We designed a series of bispecific antibodies (bsAbs) in which one arm binds to the extracellular domain of PD-L1 and the other arm targets the extracellular domain of RNF43. To optimize degradation efficiency, we screened various antibody formats and linker geometries to achieve favorable spatial orientation for target engagement and internalization. Through flow cytometry and immunofluorescence, we confirmed the co-internalization of the AbTAC-target-receptor complex. The lead AbTAC candidate demonstrated more than 85% reduction in surface PD-L1 levels within 24 hours, significantly outperforming traditional blocking antibodies in long-term signaling inhibition assays.

Client Testimonial

The BOC Sciences team demonstrated exceptional expertise in AbTAC design. Their ability to rapidly screen E3 ligase recruiters and optimize bispecific affinity allowed us to validate PD-L1 degradation much faster than anticipated. The data package provided was comprehensive and clearly demonstrated the lysosomal degradation mechanism.

Project Background

An innovative drug discovery startup focused on oncology sought to target HER2-positive cells that had developed resistance to kinase inhibitors. They proposed using an AbTAC approach to degrade HER2 directly. However, the client faced difficulties in achieving high specificity and potent degradation activity, as HER2 often recycles back to the plasma membrane. They required professional support in affinity maturation of the RNF43-binding arm and validation of the lysosomal trafficking pathway.

Our Support

We initiated the project by constructing a phage display library to identify high-affinity binders for the extracellular domains of RNF43 and HER2. We then performed knobs-into-holes (KiH) engineering to assemble the bispecific AbTAC. To reduce HER2 recycling, we optimized the AbTAC format to enhance receptor internalization and lysosomal trafficking. We employed Western blot and LC-MS/MS proteomics to quantify total protein degradation kinetics. Our team identified two AbTAC leads that achieved potent HER2 degradation, with DC50 values in the picomolar range, and showed significant growth inhibition in resistant cell lines. Furthermore, we provided detailed mechanistic evidence showing that the degradation was RNF43-dependent.

Client Testimonial

BOC Sciences provided a turnkey solution for our HER2 AbTAC project. Their technical depth in bispecific antibody engineering and protein degradation assays was pivotal in overcoming the recycling challenges we faced. We are highly satisfied with the identified candidates and the clarity of the mechanistic validation.

Why Choose Us

Why Choose BOC Sciences for Your AbTAC Project?

Integrated AbTAC Development Capability

We support AbTAC projects from target feasibility assessment and antibody selection to construct design, assay development, mechanism validation, and optimization recommendation.

Deep Understanding of Extracellular TPD

Our team helps clients evaluate AbTACs in the broader context of extracellular targeted protein degradation, including lysosomal degradation pathways and antibody-based degrader formats.

Design Logic Beyond Simple Binding

We consider epitope position, molecular geometry, receptor recruitment, internalization, trafficking, and degradation readouts to improve the probability of identifying productive AbTAC constructs.

Flexible Service Modules

Clients can select individual services such as antibody evaluation, linker design, construct preparation, degradation assays, or full end-to-end AbTAC development support.

Mechanism-Oriented Validation

We design experiments to clarify whether target reduction results from degradation, internalization, receptor dependency, lysosomal trafficking, or non-degradative surface masking.

Actionable Data for Next-Round Optimization

Our reports provide construct comparison, assay interpretation, limitation analysis, and clear recommendations to support the next stage of AbTAC research.

Frequently Asked Questions (FAQ)

Frequently Asked Questions

Still have questions?

Contact Us

What Is AbTAC Degradation Technology?

AbTAC Degradation Technology is an antibody-based targeted degradation strategy designed to remove cell-surface or extracellular proteins through receptor-mediated internalization and lysosomal degradation. It typically uses a bispecific antibody or antibody-like molecule that binds both the target protein and a cell-surface receptor involved in intracellular trafficking. Unlike traditional antibodies that mainly block, activate, or neutralize targets, AbTAC focuses on selective protein clearance, making it highly relevant for drug discovery programs involving membrane proteins, surface receptors, and challenging extracellular targets.

How Does AbTAC Degradation Technology Work?

AbTAC degradation technology works by using the dual-binding capability of antibody molecules. One binding arm recognizes a disease-relevant cell-surface target protein, while the other engages a receptor that can mediate internalization and lysosomal delivery. This interaction promotes cellular uptake of the target protein and directs it toward degradation pathways. For drug development teams, AbTAC offers a way to combine antibody specificity with targeted protein degradation, supporting research programs where simple target blocking may not provide sufficient biological insight or functional control.

What Targets Are Suitable for AbTAC?

AbTAC is generally suitable for targets located on the cell surface or in the extracellular space that can be internalized and routed to lysosomal degradation. Examples may include membrane receptors, transmembrane proteins, cell-surface ligands, and selected disease-associated extracellular proteins. Early-stage project design often requires evaluating target expression, antibody-accessible epitopes, internalization potential, and the selection of an appropriate degradation-mediating receptor. BOC Sciences can support AbTAC research through antibody-conjugate design, chemical modification, custom synthesis, and in vitro functional evaluation.

How Is AbTAC Different from PROTAC?

AbTAC and PROTAC are both targeted protein degradation strategies, but they differ in target scope and degradation mechanism. PROTACs are mainly used for intracellular proteins and typically recruit E3 ligases to drive ubiquitin-proteasome degradation. AbTAC, by contrast, is primarily designed for cell-surface and extracellular proteins and relies on antibody recognition, receptor-mediated internalization, and lysosomal degradation. BOC Sciences can help clients evaluate the suitability of different degradation technologies and support early-stage workflows from molecular design and conjugation strategy to in vitro validation.

How to Start an AbTAC Degradation Project?

Starting an AbTAC degradation project usually begins with target feasibility analysis, including whether the protein is exposed on the cell surface, whether suitable antibodies are available, whether the target can be internalized, and which receptor may support lysosomal delivery. The next steps may include bispecific antibody design, conjugation strategy optimization, binding assessment, internalization studies, and cell-based degradation evaluation. A systematic AbTAC research plan can help drug discovery teams explore membrane protein degradation more efficiently and identify promising directions for further development.